17 January 2024 - NICE has published evidence-based recommendations on the use of olaparib (Lynparza) in combination with bevacizumab (Avastin) for the treatment of adults with high grade epithelial ovarian, fallopian tube or primary peritoneal cancer.

Olaparib, when used in combination with bevacizumab is recommended for the maintenance treatment of adults with high grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer:

• Has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab
• Is advanced (International Federation of Gynecology and Obstetrics stages 3 and 4) and
• Is homologous recombination deficiency positive (defined as having either a BRCA1 or BRCA2 mutation, or genomic instability)

Read NICE technology appraisal guidance